Efficacy and safety of ustekinumab and vedolizumab in very early-onset inflammatory bowel disease: A multicenter study from the pediatric inflammatory bowel disease Porto Group of ESPGHAN.
OBJECTIVE We aimed to assess vedolizumab and ustekinumab efficacy and safety in patients with very-early onset inflammatory bowel disease (VEO-IBD). METHODS A retrospective study involving 29 European and North American sites affiliated with the IBD Porto Group of European Society for Paediatric Gastroenterology Hepa...